Our management team has a wealth of technical and medical knowledge, a strong commercial mindset and a track record in raising finance.
We are driven to develop life-changing therapeutics for patients with fibrosis and cancer and to improve the success rate of discovery by harnessing the power of our proprietary human extracellular matrix (ECM) scaffolds.
Dr Giuseppe Mazza
Chief Executive Officer and Co-Founder
Dr Giuseppe Mazza co-founded Engitix and has served as Chief Executive Officer (CEO) since the Company’s formation in 2016.
Engitix is built on Dr Mazza’s pioneering research, where he developed novel decellularisation procedures for human tissues, including whole livers, while working in the laboratory of Professor Massimo Pinzani at the Institute for Liver and Digestive Health (IDLH), Division of Medicine, University College London (UCL).
Dr Mazza was a Post-Doctoral Fellow at the UCL IDLH, where he was also responsible for operating the Tissue Engineering and Regenerative Medicine Laboratory. Dr Mazza received his PhD in Tissue Engineering and Organ Regeneration from UCL. Dr Mazza was Director R&D at Promethera Bioscience from 2015 to 2017.
He has been involved in several international healthcare organizations, including serving on the Steering Committee of the non-profit European Haemophilia Consortium (EHC). In 2011, he founded the healthcare charity Associazione Icore ONLUS, where he served as President for six years.
Dr Gino Van Heeke
Chief Scientific Officer
Dr Gino Van Heeke joined Engitix as Chief Scientific Officer (CSO) in May 2019.
Dr Van Heeke has over 20 years of experience and success in both biologics and small molecule drug discovery and development, including in fibrosis and oncology.
Before joining Engitix, he held the position of Senior Director, Discovery and Early Development, at Ablynx. During his tenure, he was responsible for a portfolio of more than 30 proprietary and partnered drug discovery projects. Previously, he held a series of positions of increasing seniority at Novartis, latterly as Executive Director in the area of Respiratory Diseases.
Dr Van Heeke began his career as a Research Scientist at Restoragen while simultaneously working at the Interdisciplinary Center for Biotechnology Research at the University of Florida. He then joined Ciba Pharmaceuticals in Basel, Switzerland before moving to Novartis.
He holds a BEng in Biochemical Engineering and a PhD in Biochemistry and Molecular Biology.
Chief Financial Officer
David Dally joined Engitix as Chief Financial Officer (CFO) in November 2018.
Mr Dally has over 20 years of experience in the biotech and pharmaceutical industry, working in finance and general management across companies of varying size, financial ownership and geographical location, including in the UK, the US and Asia.
Mr Dally is an experienced executive having held the position of CEO at MerLion Pharmaceuticals since 2013, before which he was CFO from 2007. He was also consultant CEO for Reproductive Sciences Ltd from 2016 to 2018.
During his career, Mr Dally has been CFO for several companies including KuDOS Pharmaceuticals (which was sold to AstraZeneca for $210 million), Rhytec Ltd, and Dyson. He established his career as a financial leader through various roles at Amersham plc (now GE Healthcare), latterly as Vice President of finance, North America where he oversaw the merger of Amersham Life Science with Pharmacia Biotech.
David is a chartered accountant and holds a MA in Geography from the University of Cambridge.
Chief Operating Officer
Stephen Brindle has worked at Engitix as Chief Operating Officer (COO) since the Company was formed in 2016.
Before joining Engitix, he spent 8 years as Managing Partner of Technikos LLP, a medical devices venture capital fund with a long-term commercial contract with Oxford University’s Biomedical Engineering department.
Previously, Mr Brindle spent a decade as an equity salesman latterly with Citigroup and Goldman Sachs. Between 1991 and 1997 he worked as a management consultant, latterly at Deloitte Consulting.
He holds a BSc in Economics from LSE.